TY - JOUR
T1 - Antibiotics for treatment of resistant gram-positive coccal infections
AU - Al-Tatari, Hossam
AU - Abdel-Haq, Nahed
AU - Chearskul, Pimpanada
AU - Asmar, Basim
PY - 2006/4
Y1 - 2006/4
N2 - Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasive Staphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.
AB - Vancomycin is considered the workhorse for the treatment of most drug-resistant gram-positive bacterial infections. However, concerns have been raised regarding the increasing rates of vancomycin-resistant enterococci and the clinical shortcomings of vancomycin in the treatment of invasive Staphylococcus aureus infections. Resources have been committed to the development of antimicrobial agents with activity against these organisms. This review will focus on the newer antibacterial agents that have been developed for the treatment of resistant gram-positive pathogens. Included in this review are the agents: quinupristin-dalfopristin, linezolid, daptomycin, telithromycin, and tigecycline.
KW - Antibacterial agents
KW - Bacterial infections
KW - Vancomycin,Gram-positive
UR - http://www.scopus.com/inward/record.url?scp=33746864112&partnerID=8YFLogxK
U2 - 10.1007/BF02825827
DO - 10.1007/BF02825827
M3 - Article
C2 - 16816494
AN - SCOPUS:33746864112
SN - 0019-5456
VL - 73
SP - 323
EP - 334
JO - Indian Journal of Pediatrics
JF - Indian Journal of Pediatrics
IS - 4
ER -